PM stock forecast, quote, news & analysis

Key Takeaways

• Philip Morris International shares traded near $193 in mid-July 2026, reflecting a roughly 8% gain over the trailing 30-day period, supported by steady smoke-free product momentum and strong Q1 earnings.
• Smoke-free products accounted for 43% of total net revenues in Q1 2026, with IQOS heated tobacco units delivering double-digit shipment growth and surpassing Marlboro as the company's top nicotine brand in markets where present.
• The company's Q2 2026 results are scheduled for July 22, with consensus revenue estimates of $10.56 billion and adjusted EPS of $2.04, both representing year-over-year growth.
• Wall Street maintains a Moderate Buy consensus on PM, with an average 12-month price target of $194.62 and ten out of twelve analysts rating the stock a Buy.
• The quarterly dividend of $1.47 per share translates to an annualized yield of approximately 3.1%, reinforcing PM's appeal among income-oriented investors.

Current Market Snapshot

Philip Morris International (PM) shares have demonstrated resilience through mid-2026, trading near the upper end of their 52-week range of $142.11 to $194.62. The stock's 50-day moving average sits around $182, while the 200-day moving average hovers near $174, indicating a sustained upward trend over both medium- and longer-term horizons. With a market capitalization exceeding $300 billion and a beta of 0.38, PM exhibits defensive characteristics that tend to attract capital during periods of macroeconomic uncertainty. Institutional ownership remains robust at approximately 78.6%, with major holders including Vanguard Group, Capital World Investors, and Capital International Investors all increasing their positions in recent quarters.

Philip Morris International (PM) Business Overview and Competitive Position

Philip Morris International is a leading global consumer goods company with a stated mission of delivering a smoke-free future. Spun off from Altria Group (MO) in 2008, PM operates exclusively in international markets and the U.S., manufacturing and selling cigarettes alongside a rapidly expanding portfolio of smoke-free alternatives. The company's flagship reduced-risk products include IQOS heated tobacco devices and consumables, ZYN nicotine pouches (via the Swedish Match acquisition), and VEEV e-vapor products. As of Q1 2026, smoke-free products were available in 108 markets and used by an estimated 43 million legal-age adult consumers worldwide. PM has invested more than $16 billion since 2008 in scientific research and commercialization of smoke-free alternatives, securing FDA marketing authorizations for ZYN and multiple IQOS versions — first-ever decisions in their respective categories. Effective January 2026, PMI realigned its reporting structure into three segments: International Smoke-Free, International Combustibles, and U.S., reflecting the strategic centrality of the smoke-free transition.

Recent Developments Driving PM

Several factors have shaped PM's stock performance in recent weeks. The company reported better-than-expected Q1 2026 results on April 22, posting adjusted diluted EPS of $1.96 — a 16% increase year-over-year — on net revenues of $10.15 billion, which rose 9.1%. IQOS heated tobacco unit shipments grew 11.3%, and the brand achieved a milestone by surpassing Marlboro as the number one nicotine brand in markets where both are present. The international smoke-free segment delivered 24.7% reported net revenue growth, with gross profit expanding nearly 29%. PM also reaffirmed its full-year 2026 adjusted diluted EPS guidance of $8.36 to $8.51, representing 10.9% to 12.9% growth versus 2025.

Investor attention has also been focused on the upcoming Q2 earnings release scheduled for July 22. Analysts expect revenues of $10.56 billion and EPS of $2.04, with continued IQOS strength outside the U.S., sustained combustible pricing power, and gradual normalization of ZYN channel inventories cited as key themes. On the analyst front, Morgan Stanley raised its PM price target to $200 in early June, while Needham and Bank of America reiterated Buy ratings. UBS maintained a more cautious Neutral rating with a $182 target. Institutional flows have been mixed but tilted positive overall, with several funds including Heartland Bank & Trust and Independent Financial Group initiating or significantly increasing positions during Q1.

Trending AI Robots

Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots designed to help traders navigate thousands of stocks, including consumer staples and tobacco-sector names. Tickeron offers hundreds of these automated strategies, each with distinct timeframes, risk profiles, and technical methodologies — from swing trading to longer-term trend-following approaches. Only the bots demonstrating the strongest recent performance metrics and highest relevance appear in the Trending section, giving users a filtered view of strategies that are currently generating signals worth attention. Traders looking to complement their own analysis of stocks like Philip Morris International can explore the page to see which AI-driven approaches are gaining traction in real time.

2026 Outlook and What Investors Should Watch

Looking ahead, several drivers will influence PM's trajectory. The Q2 2026 earnings report on July 22 will provide the next major catalyst, with particular scrutiny on IQOS volume trends in Japan following April's excise-driven price increases, ZYN shipment recovery in the U.S., and VEEV's expanding profitability in Europe. The company's full-year 2026 forecast assumes 5% to 7% organic net revenue growth and 7% to 9% organic operating income growth, underpinned by high-single-digit smoke-free volume expansion.

Regulatory developments remain a critical variable. The FDA's ongoing review of ZYN ULTRA under the nicotine pouch pilot program, potential flavor ban expansions in European markets, and evolving global tobacco excise policies all carry implications for PM's product mix and margin trajectory. Additionally, the company's long-term ambition to expand into wellness and life sciences beyond nicotine — though still in early stages — could reshape its investment narrative over the coming years. Macroeconomic factors including currency fluctuations, energy costs, and consumer spending resilience in key markets such as Europe, Japan, and Southeast Asia will also play significant roles in shaping performance against management's stated targets.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations